SHR2554; Chidamide analog tablets

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy

Drug Information

Target Indication

Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy

Clinical Trial

Last updated: 1/7/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

JNGHF

Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR

Related Pipeline

KNEE OSTEOARTHRITIS

Advanced Solid Tumor

Carcinoma, Hepatocellular

PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer

Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts